BCLI Stock Price, BrainStorm Cell Therapeutics Quote, Chart

Market Summary

USD0.520.00

Delayed

0.00%

BCLI Stock Price

View Fullscreen

BCLI RSI Chart

BCLI Valuation

Market Cap

36.4M

Price/Earnings (Trailing)

-2.35

Price/Free Cashflow

-1.86

BCLI Price/Sales (Trailing)

BCLI Profitability

Return on Equity

279.89%

Return on Assets

-463.98%

Free Cashflow Yield

-53.66%

BCLI Fundamentals

BCLI Earnings

Earnings (TTM)

-15.5M

Earnings Growth (Yr)

32.77%

Earnings Growth (Qtr)

39.03%

Breaking Down BCLI Revenue

Last 7 days

13.0%

Last 30 days

-3.7%

Last 90 days

40.5%

Trailing 12 Months

-81.2%

How does BCLI drawdown profile look like?

BCLI Financial Health

Current Ratio

0.18

BCLI Investor Care

Shares Dilution (1Y)

77.83%

Diluted EPS (TTM)

-0.32

Tracking the Latest Insider Buys and Sells of BrainStorm Cell Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	lebovits chaim	acquired	24,816	0.3743	66,300	president & ceo
May 06, 2024	lebovits chaim	acquired	50,665	0.3753	135,000	president & ceo
Apr 19, 2024	lebovits chaim	acquired	7,798	0.5199	15,000	president & ceo
Apr 18, 2024	lebovits chaim	acquired	60,470	0.5255	115,072	president & ceo
Apr 17, 2024	lebovits chaim	acquired	70,941	0.5457	130,000	president & ceo
Mar 11, 2024	yablonka uri	acquired	-	-	109,426	evp & chief business officer
Mar 11, 2024	lebovits chaim	acquired	-	-	305,198	president & ceo
Mar 11, 2024	lindborg stacy	acquired	-	-	241,935	co-chief executive officer
Mar 11, 2024	patlis alla	acquired	-	-	65,246	see remarks
Sep 01, 2023	lindborg stacy	bought	20,402	1.7741	11,500	co-chief executive officer

Which funds bought or sold BCLI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	10,578	10,578	-%
May 15, 2024	STATE STREET CORP	unchanged	-	28,021	54,245	-%
May 15, 2024	MORGAN STANLEY	reduced	-22.07	8,597	22,643	-%
May 15, 2024	Royal Bank of Canada	reduced	-41.73	-	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-39.65	1,240	6,218	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	1,225	2,372	-%
May 15, 2024	Ikarian Capital, LLC	unchanged	-	26,324	50,960	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-5.12	277	564	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	15,982	30,939	-%
May 14, 2024	Clearstead Advisors, LLC	new	-	822	822	-%

Are Funds Buying or Selling BCLI?

Are funds buying BCLI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCLI

No. of Funds

Unveiling BrainStorm Cell Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	ness kevin dean	6.25%	3,060,000	SC 13G/A
Apr 05, 2023	ness kevin dean	9.98%	3,660,000	SC 13G/A
Feb 14, 2022	abbhi investments, llc	6.69%	2,425,853	SC 13G
Feb 04, 2022	ness kevin dean	9.1%	3,300,000	SC 13G
Jul 12, 2021	blackrock inc.	1.3%	474,347	SC 13G/A
Feb 02, 2021	blackrock inc.	6.1%	1,920,340	SC 13G
May 08, 2020	daly joseph patrick	3.66%	1,077,500	SC 13D/A
Apr 08, 2020	abbhi investments, llc	9.03%	2,367,751	SC 13D
Mar 18, 2020	abbhi investments, llc	9.03%	2,367,751	SC 13G
Nov 21, 2019	daly joseph patrick	4.58%	1,035,181	SC 13D

Recent SEC filings of BrainStorm Cell Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 03, 2024	8-K	Current Report
Apr 25, 2024	4	Insider Trading
Apr 22, 2024	3	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 17, 2024	8-K	Current Report
Apr 11, 2024	8-K	Current Report

Peers (Alternatives to BrainStorm Cell Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

BrainStorm Cell Therapeutics Inc News

Latest updates

BrainStorm Cell Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-20.4%	3,348	4,208	5,682	5,747	7,872	8,451	13,254	18,961	25,791	29,277	34,538	42,235	48,571	51,259	32,691	19,221	18,071	6,534	7,811	8,864	11,851
Current Assets	-33.7%	1,259	1,899	1,539	1,213	2,929	3,106	7,502	12,806	19,260	23,280	27,944	35,187	41,030	43,242	30,337	16,628	15,205	3,360	4,672	5,535	8,257
Cash Equivalents	-26.1%	961	1,300	1,222	546	2,021	772	4,144	9,005	15,151	18,856	25,695	30,565	35,933	37,829	24,770	12,153	12,471	536	2,095	1,126	3,238
Net PPE	-9.3%	622	686	752	799	866	933	1,003	1,072	1,124	1,189	1,224	1,054	1,088	1,119	950	918	918	960	664	599	611
Liabilities	-1.9%	8,898	9,066	8,264	9,629	12,712	11,466	11,866	11,110	11,304	9,935	9,612	12,063	12,370	15,795	6,713	9,399	9,060	18,757	14,588	13,380	11,525
Current Liabilities	-12.4%	6,831	7,800	6,321	7,691	10,422	8,800	8,948	7,846	7,372	6,317	5,846	8,059	8,191	11,233	6,429	8,840	8,252	17,654	11,958	10,543	8,480
Shareholder's Equity	-14.2%	-5,550	-4,858	-	-	-4,840	-3,015	1,388	7,851	14,487	19,342	24,926	30,172	36,201	35,464	25,978	9,822	9,011	-	-	-	326
Retained Earnings	-1.4%	-218,000	-215,013	-209,000	-208,209	-202,880	-197,821	-193,000	-186,000	-179,000	-173,544	-167,000	-162,018	-155,749	-149,087	-137,272	-132,784	-125,390	-117,276	-109,584	-103,950	-99,050
Additional Paid-In Capital	1.3%	212,967	210,258	206,957	204,431	198,144	194,910	194,295	193,900	193,495	192,990	192,384	192,294	192,054	184,655	163,238	142,594	134,389	105,042	102,796	99,423	98,325
Shares Outstanding	13.0%	68,342	60,489	45,315	40,927	38,475	36,694	36,493	36,486	36,437	36,401	36,305	36,319	35,791	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	-	78,887	-	-	-	119,594	-	-	-	278,375	-	-	-	75,374	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	6.8%	-3,063	-3,285	-6,409	-6,778	-3,986	-4,648	-4,850	-6,134	-3,688	-5,508	-6,460	-5,329	-8,968	-7,578	-6,924	-5,662	-15,029	-3,278	-3,626	-3,508	-835
Share Based Compensation	-	170	-	-	-	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-100.0%	-	196	-12.00	4.00	2,005	1,038	-11.00	-12.00	-17.00	-1,297	1,696	-39.00	-37.00	-302	-86.00	-2,070	-1,994	-345	1,439	1,391	3,131
Cashflow From Financing	-24.3%	2,539	3,352	7,097	5,299	3,230	-	-	-	-	-34.00	-106	-	7,109	20,939	19,627	7,414	28,958	2,064	3,156	5.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BCLI Income Statement

2024-03-31

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development, net	$ 961	$ 2,924
General and administrative	1,513	2,227
Operating loss	(2,474)	(5,151)
Financial income, net	13	92
Loss on change in fair value of Warrants liability (Note 6)	(940)
Net loss	$ (3,401)	$ (5,059)
Basic net loss per share from continuing operations	$ (0.05)	$ (0.14)
Diluted net loss per share from continuing operations	$ (0.05)	$ (0.14)
Weighted average number of shares outstanding used in computing basic net loss per share	64,738,544	36,735,435
Weighted average number of shares outstanding used in computing diluted net loss per share	64,738,544	36,735,435

BCLI Balance Sheet

2024-03-31

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 779	$ 1,300
Other accounts receivable	26	51
Prepaid expenses and other current assets (Note 4)	454	548
Total current assets	1,259	1,899
Long-Term Assets:
Prepaid expenses and other long-term assets	20	22
Restricted Cash	182	185
Operating lease right of use asset (Note 5)	1,265	1,416
Property and Equipment, Net	622	686
Total Long-Term Assets	2,089	2,309
Total assets	3,348	4,208
Current Liabilities:
Accounts payables	4,690	4,954
Accrued expenses	636	1,240
Operating lease liability (Note 5)	588	603
Employees related liability	917	1,003
Total current liabilities	6,831	7,800
Long-Term Liabilities:
Operating lease liability (Note 5)	533	672
Warrants liability (Note 6)	1,534	594
Total long-term liabilities	2,067	1,266
Total liabilities	8,898	9,066
Stockholders' Deficit:
Stock capital: (Note 7) Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at March 31, 2024 and December 31, 2023 respectively; Issued and outstanding: 68,447,193 and 60,489,208 shares at March 31, 2024 and December 31, 2023 respectively.	13	13
Additional paid-in-capital	212,967	210,258
Treasury stocks	(116)	(116)
Accumulated deficit	(218,414)	(215,013)
Total stockholders' deficit	(5,550)	(4,858)
Total liabilities and stockholders' deficit	$ 3,348	$ 4,208

About BrainStorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

CEO	Mr. Chaim Lebovits
WEBSITE	brainstorm-cell.com
INDUSTRY	Biotechnology
EMPLOYEES	44

BrainStorm Cell Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for BrainStorm Cell Therapeutics Inc? What does BCLI stand for in stocks?

BCLI is the stock ticker symbol of BrainStorm Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BrainStorm Cell Therapeutics Inc (BCLI)?

As of Fri May 17 2024, market cap of BrainStorm Cell Therapeutics Inc is 36.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCLI stock?

You can check BCLI's fair value in chart for subscribers.

What is the fair value of BCLI stock?

You can check BCLI's fair value in chart for subscribers. The fair value of BrainStorm Cell Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BrainStorm Cell Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCLI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BrainStorm Cell Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BCLI is over valued or under valued. Whether BrainStorm Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact BrainStorm Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCLI.

What is 5 year return on BrainStorm Cell Therapeutics Inc's stock?

In the past 10 years, BrainStorm Cell Therapeutics Inc has provided -0.179 (multiply by 100 for percentage) rate of return.